BOT is working to advance its BTX1503 acne treatment to a Phase 3 study and is expecting to start the study when COVID-19 restrictions ease. The Company is also planning to kick off its BTX1801 anti-microbial study this month in WA. While we are encouraged by the progression of the studies and the anti-microbial potential, we are however still cautious until BOT releases a successful set of results. We maintain our HOLD recommendation with a $0.06 price target.
To access the full report please log in under the Client Area at the bottom of this page.
Argonaut’s Client Area allows you to view delayed share prices, access Argonaut’s wealth of Research as well as create custom portfolios and set up company watch lists.
If you would like to access our research please contact us to create an account.